{"cluster": 50, "subcluster": 3, "abstract_summ": "The unprecedented challenges posed by the coronavirus disease 2019 (COVID\u201019) pandemic highlight the urgency for applying clinical pharmacology and model\u2010informed drug development in (i) dosage optimization for COVID\u201019 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non\u2013COVID\u201019 trials.Here, we review currently registered interventional clinical trials for the treatment and prevention of COVID-19 to provide an overall summary and insight into the global response.The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions.This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials.Though most drug development takes years from discovery to approval, for the COVID-19 pandemic, drug development is on a fundamentally different timeline.", "title_summ": "An Opportunity for Clinical PharmacologyClinical trials and Haemophilia during the COVID\u201019\u2019 pandemic: Madrid\u2019s ExperienceWhere are we now with COVID\u201019?What can vaccines learn from aviation?Current regulatory approaches for accessing potential COVID-19 therapiesTime to step up: A call to action for the clinical and quantitative pharmacology community to accelerate therapeutics for COVID\u201019Clinical trials during COVID\u201019The Case for Why Africa Should Host COVID-19 Candidate Vaccine TrialsTeamwork, A Novel Concept During an Infectious Pandemic?COVID-19: a defining moment for clinical pharmacology?The COVID-19 pandemic: is our medicine still evidence-based?Conducting Clinical Trials During the COVID-19 Pandemic.Ongoing Clinical Trials for the Management of the COVID-19 PandemicChallenges in Drug Development Posed by the COVID\u201019 Pandemic:", "title_abstract_phrases": "An Opportunity for Clinical PharmacologyThe unprecedented challenges posed by the coronavirus disease 2019 (COVID\u201019) pandemic highlight the urgency for applying clinical pharmacology and model\u2010informed drug development in (i) dosage optimization for COVID\u201019 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non\u2013COVID\u201019 trials.Here, we review currently registered interventional clinical trials for the treatment and prevention of COVID-19 to provide an overall summary and insight into the global response.Current regulatory approaches for accessing potential COVID-19 therapiesThis commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials.The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions.The Case for Why Africa Should Host COVID-19 Candidate Vaccine TrialsIn response to provocative comments by 2 European clinicians and scientists, the World Health Organization Director General has declared that Africa will not host COVID-19 vaccine trials."}